© Website designed by Alasdair Coles, 2012
What is the “CAM-THY” trial?
The purpose of this trial is to try and prevent side effects of
alemtuzumab - a drug which has been tested in clinical trials as a
treatment of multiple sclerosis.
Although alemtuzumab is an effective treatment of multiple sclerosis,
it has side effects, in particular 1 in 3 patients develop a new
autoimmune disease after treatment. In other words, as their immune
system grows back, it begins to attack other parts of their body; most
commonly the thyroid gland.
We believe that we can reduce the risk of autoimmune disease after
treatment with alemtuzumab by using a drug which alters the way in
which the immune system grows back. Kepivance (also known as
Palifermin) has been shown to do this in animals. It works by boosting
the function of the thymus, a gland in the neck which makes new
immune cells. This study is testing whether or not Kepivance will boost
thymus function in humans.
Who will be recruited to the trial?
We are looking for people with relapsing-remitting mutiple sclerosis,
within ten years of the first symptoms of multiple sclerosis, who can
walk without aids and who have had at least 2 clinical episodes of MS
in the previous 2 years. These relapses may have occurred whilst on
What is happening on the trial?
Because we don’t know for certain that Kepivance will prevent
autoimmunity after alemtuzumab treatment, half of all patients in this
study will be assigned to receive Kepivance and the other half will be
assigned to receive a "dummy drug", called a placebo. It looks the
same as the Kepivance treatment but does not contain any of the
active ingredients and will have no effect on you. This process will
done in a random way (by chance) - much like flipping a coin. You will
have a 50% chance of receiving Kepivance. All people will be treated
with alemtuzumab. Both alemtuzumab and Kepivance have side-
effects, some of which are serious.
More details can be found here
Patient Information Sheet
How can I be considered for the trial?
Please discuss this trial with your GP or neurologist. If together you
decide it would be appropriate to be considered, please ask them to
refer you to:
Dr Alasdair Coles
Cambridge CB2 2QQ
A new clinical trial of alemtuzumab
This page has been approved by the RES Committee London - Hampstead, on 16th May 2012